BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 19776461)

  • 1. [Bayesian approach for the cost-effectiveness evaluation of healthcare technologies].
    Berchialla P; Gregori D; Brunello F; Veltri A; Petrinco M; Pagano E
    Epidemiol Prev; 2009; 33(3):123-8. PubMed ID: 19776461
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bayesian methods for design and analysis of cost-effectiveness trials in the evaluation of health care technologies.
    O'Hagan A; Stevens JW
    Stat Methods Med Res; 2002 Dec; 11(6):469-90. PubMed ID: 12516985
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Complementing the net benefit approach: a new framework for Bayesian cost-effectiveness analysis.
    Hernández MA; Vázquez-Polo FJ; González-Torre FJ; Bas EM
    Int J Technol Assess Health Care; 2009 Oct; 25(4):537-45. PubMed ID: 19845984
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Bayesian model averaging approach with non-informative priors for cost-effectiveness analyses.
    Conigliani C
    Stat Med; 2010 Jul; 29(16):1696-709. PubMed ID: 20572119
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Bayesian approach to stochastic cost-effectiveness analysis.
    Briggs AH
    Health Econ; 1999 May; 8(3):257-61. PubMed ID: 10348420
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Bayesian approach to stochastic cost-effectiveness analysis. An illustration and application to blood pressure control in type 2 diabetes.
    Briggs AH
    Int J Technol Assess Health Care; 2001; 17(1):69-82. PubMed ID: 11329846
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Incremental cost-effectiveness ratio and incremental net-health benefit: two sides of the same coin.
    Craig BA; Black MA
    Expert Rev Pharmacoecon Outcomes Res; 2001 Oct; 1(1):37-46. PubMed ID: 19807506
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Estimating Value-Based Price and Quantifying Uncertainty around It in Health Technology Assessment: Frequentist and Bayesian Approaches.
    Hagiwara Y; Shiroiwa T
    Med Decis Making; 2022 Jul; 42(5):672-683. PubMed ID: 35172648
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bayesian cost-effectiveness analysis with two measures of effectiveness: the cost-effectiveness acceptability plane.
    Negrín MA; Vázquez-Polo FJ
    Health Econ; 2006 Apr; 15(4):363-72. PubMed ID: 16259048
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Advantages of using the net-benefit approach for analysing uncertainty in economic evaluation studies.
    Zethraeus N; Johannesson M; Jönsson B; Löthgren M; Tambour M
    Pharmacoeconomics; 2003; 21(1):39-48. PubMed ID: 12484802
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An illustration of the modelling of cost and efficacy data from a clinical trial.
    Hahn S; Whitehead A
    Stat Med; 2003 Mar; 22(6):1009-24. PubMed ID: 12627415
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Incorporation of genuine prior information in cost-effectiveness analysis of clinical trial data.
    Stevens JW; O'Hagan A
    Int J Technol Assess Health Care; 2002; 18(4):782-90. PubMed ID: 12602079
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bayesian cost-effectiveness analysis from clinical trial data.
    O'Hagan A; Stevens JW; Montmartin J
    Stat Med; 2001 Mar; 20(5):733-53. PubMed ID: 11241573
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inference for the cost-effectiveness acceptability curve and cost-effectiveness ratio.
    O'Hagan A; Stevens JW; Montmartin J
    Pharmacoeconomics; 2000 Apr; 17(4):339-49. PubMed ID: 10947489
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Presenting evidence and summary measures to best inform societal decisions when comparing multiple strategies.
    Eckermann S; Willan AR
    Pharmacoeconomics; 2011 Jul; 29(7):563-77. PubMed ID: 21671686
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Handling uncertainty in economic evaluations of patient level data: a review of the use of Bayesian methods to inform health technology assessments.
    McCarron CE; Pullenayegum EM; Marshall DA; Goeree R; Tarride JE
    Int J Technol Assess Health Care; 2009 Oct; 25(4):546-54. PubMed ID: 19845985
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bayesian decision-theoretic group sequential clinical trial design based on a quadratic loss function: a frequentist evaluation.
    Lewis RJ; Lipsky AM; Berry DA
    Clin Trials; 2007; 4(1):5-14. PubMed ID: 17327241
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Incorporating model uncertainty in cost-effectiveness analysis: a Bayesian model averaging approach.
    Negrín MA; Vázquez-Polo FJ
    J Health Econ; 2008 Sep; 27(5):1250-9. PubMed ID: 18490067
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bayesian approaches to multiple sources of evidence and uncertainty in complex cost-effectiveness modelling.
    Spiegelhalter DJ; Best NG
    Stat Med; 2003 Dec; 22(23):3687-709. PubMed ID: 14652869
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A new approach for sample size calculation in cost-effectiveness studies based on value of information.
    Bader C; Cossin S; Maillard A; Bénard A
    BMC Med Res Methodol; 2018 Oct; 18(1):113. PubMed ID: 30348087
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.